Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion

该计划将高达2,500万美元的新资本与300万美元现有债务的重组相结合，以支持商业化落地和生产扩张

Company anticipates positive monthly operating cash flow by the end of Q1 2027

公司预计在2027年第一季度末实现月度经营性现金流为正

Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline

菲利普·A·巴拉奇将加入董事会，带来财务专业知识并注重资本纪律

FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced an initial closing generating over $10 million in gross cash proceeds from a private placement of senior secured convertible notes and warrants.

新泽西州弗洛勒姆帕克，2026年9月24日（环球电讯社）——再生与细胞医学公司Celularity Inc.（纳斯达克股票代码：CELU）（“Celularity”或“公司”）今日宣布，通过私募发行高级有担保可转换票据及认股权证，完成首次交割，募集毛现金收益超过1,000万美元。

The closing is part of a broader recapitalization plan contemplating up to $25 million in new cash investment, including the initial closing, and the restructuring of approximately $3 million in existing indebtedness..

此次交割是更广泛资本重组计划的一部分，该计划拟进行总额高达2,500万美元的新现金投资（包括首次交割），并对约300万美元的现有债务进行重组。

The financing follows significant operating improvements, including a reduction in monthly cash burn of more than $1 million, personnel optimization and a sharper allocation of resources toward revenue-generating opportunities. With a lower operating cost base, purpose-built manufacturing infrastructure and existing cenplacel-L inventory that management estimates represents approximately $40 million in potential sales value, Celularity is focused on converting its scientific and manufacturing assets into revenue and sustained growth..

此次融资紧随一系列重大运营改善之后，包括每月现金消耗减少超过100万美元、人员优化以及将资源更集中地配置于创收机会。凭借更低的运营成本基础、专为目的建造的制造基础设施，以及管理层估计潜在销售价值约为4,000万美元的现有cenplacel-L库存，Celularity正致力于将其科学和制造资产转化为收入并实现可持续增长。

The Company also announced the appointment of Philip A. Barach to its Board of Directors, bringing financial expertise and an emphasis on capital allocation, operating accountability and stockholder returns.

该公司还宣布任命菲利普·A·巴拉奇（Philip A. Barach）为其董事会成员，为董事会带来财务专业知识，并强调资本配置、运营问责制和股东回报。

“We have built substantial scientific and manufacturing capabilities, and we are taking decisive action to translate those investments into commercial results,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer. “Our lower cost structure, existing cellular product inventory and purpose-built manufacturing facility provide a powerful foundation for growth.

“我们已经建立了强大的科研和制造能力，并正在采取果断行动，将这些投资转化为商业成果。”董事长兼首席执行官罗伯特·J·哈里里医学博士、哲学博士表示。“我们更低的成本结构、现有的细胞产品库存以及专门建造的制造设施，为增长提供了坚实的基础。

This financing supports our ambition to expand revenue-producing relationships, increase utilization of our manufacturing capabilities and pursue opportunities across cellular and regenerative medicine and complementary longevity therapeutics. Our objective is to build a business that can help advance human healthspan while delivering lasting value to stockholders.”.

此次融资支持我们拓展创收合作关系、提高制造能力利用率，并在细胞与再生医学以及互补性长寿疗法领域寻求机遇。我们的目标是打造一家既能推动延长人类健康寿命，又能为股东创造持久价值的企业。

“Extending healthy human life is an extraordinary opportunity, and Celularity has spent years building capabilities to help address it,” added Peter H. Diamandis, M.D., Co-Founder and Director of Celularity. “The next phase is about translating that foundation into scale by connecting our science with market access, expanding productive partnerships and making our infrastructure an engine of growth.

“延长人类健康寿命是一个非凡的机遇，Celularity 多年来一直致力于构建应对这一挑战的能力。”Celularity 联合创始人兼董事 Peter H. Diamandis 博士补充道。“下一阶段的重点是通过将我们的科学与市场准入相结合、拓展富有成效的合作伙伴关系，并使我们的基础设施成为增长引擎，从而将这一基础转化为规模化发展。”

I’m pleased to welcome Philip to the Board and look forward to James joining us as we work to realize that potential.”.

我很高兴欢迎菲利普加入董事会，并期待詹姆斯的加入，我们将共同努力实现这一潜力。

A Lower Cost Base and a Sharper Focus on Returns

更低的成本基础与对回报的更聚焦

Celularity has implemented substantial budgetary improvements, reduced monthly cash burn by more than $1 million and optimized personnel and spending around its strategic priorities. These actions are designed to make invested capital go further and strengthen the Company’s ability to translate additional revenue into improved operating performance..

Celularity 已实施重大的预算改进措施，将每月现金消耗减少了超过 100 万美元，并围绕其战略重点优化了人员配置和支出。这些举措旨在提高投入资本的使用效率，增强公司将额外收入转化为更优运营表现的能力。

Building on these operating improvements and anticipated revenue growth, Celularity expects to achieve positive monthly operating cash flow by the end of the first quarter of 2027. This outlook reflects management’s expectations for increased manufacturing revenue, deployment of existing cellular product inventory and continued control of operating expenses..

基于这些运营改善和预期的收入增长，Celularity 预计到2027年第一季度末实现月度运营现金流为正。这一展望反映了管理层对制造收入增加、现有细胞产品库存的部署以及持续控制运营费用的预期。

“Since my initial investment, Celularity has demonstrated the willingness to make difficult operating decisions and reduce its monthly cash burn, enabling the Company to concentrate resources on bolstering revenue generation,” said Philip A. Barach. “That progress was a catalyst for my additional investment and my agreement to join the Board.

菲利普·A·巴拉赫表示：“自从我最初投资以来，Celularity 展现了做出艰难运营决策并减少每月现金消耗的决心，使公司能够集中资源加强收入生成。”“这一进展促使我进行追加投资，并同意加入董事会。”

I see an opportunity to pair a leaner operating structure with substantial scientific and manufacturing assets to build a stronger, more valuable company. My focus will be on directing capital toward the most compelling opportunities and holding the business accountable for measurable results.”.

我看到一个机会，将更精简的运营结构与强大的科学和制造资产相结合，以打造一家更强大、更有价值的公司。我的重点将是把资本导向最具吸引力的机会，并确保业务实现可衡量的成果。

Expanding Manufacturing Relationships

拓展制造合作关系

The Company’s growth strategy centers on turning its existing scientific and manufacturing assets into revenue-producing partnerships. Its

该公司的增长战略核心在于将其现有的科研与制造资产转化为创收的合作伙伴关系。其

collaboration with MuseCell Innovations Pte. Ltd. (“MCI”)

与MuseCell Innovations Pte. Ltd.（“MCI”）的合作

illustrates that strategy, establishing U.S. manufacturing capabilities for the Dezawa MuseCell® platform and related products at Celularity’s Florham Park facility. The relationship provides an opportunity to increase facility utilization, generate manufacturing revenue and build a foundation for broader commercial expansion.

阐述了该战略，即在Celularity位于Florham Park的设施中，为Dezawa MuseCell®平台及相关产品建立美国制造能力。这种合作关系为提高设施利用率、创造制造收入并为更广泛的商业扩张奠定基础提供了机会。

Celularity intends to pursue additional relationships that similarly put its existing infrastructure and expertise to productive use while maintaining a disciplined approach to capital investment..

Celularity 旨在寻求更多类似的合作关系，以有效利用其现有基础设施和专业能力，同时在资本投资方面保持审慎 disciplined 的策略。

Approximately $40 Million in Potential Sales From Existing cenplacel-L Inventory

现有 cenplacel-L 库存的潜在销售额约为 4000 万美元

Celularity currently holds inventory of cenplacel-L, its investigational placenta-derived allogeneic cell therapy, that management estimates represents approximately $40 million in potential sales value. The Company intends to pursue deployment through commercial relationships in permissive jurisdictions where supply and use are legally authorized, subject to applicable local regulatory requirements..

Celularity 目前持有其研究性胎盘来源同种异体细胞疗法 cenplacel-L 的库存，管理层估计该库存的潜在销售价值约为 4,000 万美元。公司计划在法律允许供应和使用的司法管辖区，通过商业合作关系推进该产品的部署，但须遵守适用的当地监管要求。

This existing inventory provides a tangible foundation for the Company’s domestic and international growth strategy. Celularity aims to convert that inventory into revenue while expanding relationships that can support recurring demand and broader utilization of its manufacturing capabilities.

现有库存为公司的国内外增长战略提供了切实的基础。Celularity 旨在将该库存转化为收入，同时拓展能够支持持续性需求并更广泛利用其制造能力的合作关系。

Transaction Summary

交易摘要

The transaction combines a private placement of senior secured convertible notes and accompanying warrants with the restructuring of existing indebtedness. The initial closing generated over $10 million in gross cash proceeds, before transaction expenses and repayment of existing indebtedness.

该交易将高级担保可转换票据及配套认股权证的私募配售与现有债务重组相结合。在扣除交易费用及偿还现有债务之前，首次交割产生的毛现金收益超过1,000万美元。

The notes mature 24 months after their respective issuance dates and bear interest at 10% per annum, compounded annually. Notes issued at the initial closing are initially convertible into Class A common stock at $1.50 per share. Accompanying five-year warrants are initially exercisable at $1.50 per share and provide eleven warrant shares for every twenty shares initially issuable upon conversion of the notes..

该票据在各自发行之日起24个月后到期，年利率为10%，按年复利计算。在首次交割时发行的票据，初始可按每股1.50美元的价格转换为A类普通股。附带的五年期认股权证初始行权价格为每股1.50美元，每二十股因票据转换而初始可发行的股份对应十一股认股权证股份。

Conversion and exercise prices are subject to adjustment, and issuances remain subject to applicable ownership limitations and Nasdaq stockholder approval requirements. Additional closings are subject to the applicable investor election procedures and other conditions specified in the definitive agreements.

转换价格和行权价格可能会进行调整，且证券发行仍须遵守适用的所有权限制以及纳斯达克的股东批准要求。后续交割须符合适用的投资者选择程序以及最终协议中规定的其他条件。

The full recapitalization amount includes potential future funding that has not yet been received, and there can be no assurance that additional closings will occur..

全额资本重组金额包括尚未收到的潜在未来资金，且无法保证将进行额外的交割。

In connection with the transaction, Philip A. Barach is to join Robert J. Hariri and Peter H. Diamandis on a newly constituted five-member Board of Directors, with two additional directors to be announced at a later date. The appointments remain subject to applicable requirements, including completion of the Rule 14f-1 information statement process..

在此次交易的相关安排中，Philip A. Barach 将加入新组建的五人董事会，与 Robert J. Hariri 和 Peter H. Diamandis 共同任职，另外两名董事将在日后公布。上述任命仍须满足适用要求，包括完成《14f-1 规则》信息声明程序。

Odeon Capital Group LLC acted as placement agent in connection with the initial closing of the private placement.

Odeon Capital Group LLC 在私募发行的首次交割中担任配售代理。

Further details regarding the financing, restructured indebtedness, Board arrangements and related agreements will be included in a Current Report on Form 8-K.

有关融资、债务重组、董事会安排及相关协议的进一步详情将载入一份8-K表格的当前报告。

The securities have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption. This release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale in a jurisdiction where such offer, solicitation or sale would be unlawful..

上述证券未根据经修订的《1933年证券法》或适用的州证券法律进行注册，除非完成注册或适用豁免情形，否则不得在美国境内要约或出售。本新闻稿不构成出售证券的要约，也不构成购买证券要约的招揽，且在要约为、招揽行为或销售行为属违法的任何司法管辖区，均不得进行任何销售。

About Celularity

关于 Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease.

Celularity Inc.（纳斯达克股票代码：CELU）是一家专注于长寿领域的再生与细胞医学公司，致力于开发和生产源自产后胎盘的异体及自体细胞疗法。Celularity 利用胎盘独特的生物学特性、免疫学属性以及可规模化获取的优势，开发针对衰老基本机制及年龄相关疾病的治疗解决方案。

Celularity’s cellular therapy portfolio includes cenplacel-L, its placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built facility supporting the development and manufacture of cellular therapies, advanced biomaterials, and other longevity and wellness-focused products..

Celularity的细胞治疗产品组合包括其胎盘来源的同种异体细胞疗法cenplacel-L，以及其他在研细胞疗法。Celularity总部位于新泽西州弗洛勒姆帕克，在那里运营着一座专门建造的设施，支持细胞疗法、先进生物材料以及其他专注于长寿和健康的产品开发与生产。

For more information, please visit

欲了解更多信息，请访问

www.celularity.com

www.celularity.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding potential additional financing closings and the total recapitalization amount; anticipated benefits of the financing and debt restructuring; intended use of proceeds; the anticipated appointment Board members; the sustainability and expected benefits of operating improvements and reduced cash burn; commercial execution, revenue generation and growth, including the anticipated achievement of positive monthly operating cash flow by the end of the first quarter of 2027; the estimated potential sales value, deployment and monetization of existing cenplacel-L inventory; international market access and demand; the anticipated benefits and potential expansion of the MCI collaboration and other commercial relationships; cellular, regenerative and complementary longevity-related therapeutic opportunities; and manufacturing services, utilization, capabilities and expansion.

本新闻稿包含适用联邦证券法律定义下的前瞻性陈述，包括有关潜在额外融资交割及总资本重组金额的陈述；融资和债务重组的预期收益；募集资金的预期用途；预期委任的董事会成员；运营改善和减少现金消耗的可持续性及预期收益；商业执行、收入生成和增长，包括预计在2027年第一季度末实现月度运营现金流转正；现有cenplacel-L库存的估计潜在销售价值、部署和变现；国际市场准入和需求；MCI合作及其他商业关系的预期收益和潜在扩展；细胞、再生和互补的长寿相关治疗机会；以及制造服务、利用率、能力和扩展。

These statements are based on current expectations and assumptions and are not guarantees of future performance..

这些陈述基于当前的预期和假设，并不构成对未来业绩的保证。

Actual results could differ materially due to risks and uncertainties, including the Company’s ability to obtain additional funding, satisfy its obligations and continue operations; the secured nature of its indebtedness and consequences of defaults; dilution from conversion of notes and exercise of warrants; satisfaction of conditions to additional closings and the anticipated Board appointment; obtaining stockholder approvals and meeting registration obligations; completing delinquent SEC filings and regaining or maintaining compliance with Nasdaq listing requirements; sustaining cost reductions while maintaining necessary personnel and capabilities; achieving anticipated revenue growth and cash collections within expected timeframes; securing and maintaining authorizations for the supply and use of investigational products; realizing assumed pricing and demand for existing inventory before expiration or obsolescence; clinical, regulatory, manufacturing and intellectual property risks; and the ability of the Company and its collaborators to perform their obligations and develop commercially viable opportunities..

实际结果可能因各种风险和不确定性而与预期存在重大差异，这些风险和不确定性包括：公司获得额外融资、履行义务及持续经营的能力；其债务的担保性质及违约后果；票据转换和认股权证行使导致的股权稀释；满足额外交割条件及预期的董事会任命事宜；获得股东批准并履行注册义务；完成逾期的美国证券交易委员会（SEC）文件提交，并恢复或保持符合纳斯达克上市要求；在维持必要人员和能力的同时持续降低成本；在预期时间内实现预期的收入增长和现金回收；确保并维持对研究性产品的供应和使用的授权；在库存过期或过时前实现假设的定价和需求；临床、监管、制造和知识产权方面的风险；以及公司及其合作方履行义务和开发具有商业可行性机会的能力。

Additional risks are described under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and readers should not place undue reliance on them. Except as required by law, Celularity undertakes no obligation to update or revise these statements..

额外风险在公司向美国证券交易委员会提交的文件中的“风险因素”部分及其他章节中有所描述。前瞻性陈述仅反映本新闻稿发布之日的情况，读者不应对其产生过度依赖。除非法律另有要求，Celularity 公司不承担更新或修改这些陈述的义务。

Investor and Media Contact

投资者与媒体联系人

info@celularity.com

info@celularity.com